Laurie Hollis Glimcher

6399322, Jun 4, 2002

Mar 9, 1999

09/265314

Laurie H. Glimcher - West Newton MA
I-Cheng Ho - Newton MA

President and Fellows of Harvard College - Cambridge MA

C12Q 100

435 29, 435 6, 4353201, 435 691, 4352542, 435325, 435455, 536 231, 530350

Methods for modulating production of a T helper type 2 (Th2)-associated cytokine, in particular interleukin-4, by modulating the activity of a transcription factor, in particular the proto-oncoprotein c-Maf, that regulates expression of the Th2-associated cytokine gene are disclosed. Methods for modulating development of T helper type 1 (Th1) or T helper type 2 (Th2) subsets in a subject using agents that modulate transcription factor activity are also disclosed. The methods of the invention can further involve use of agents that modulate the activity of additional transcription factors that contribute to the regulation of Th1- or Th2-associated cytokines, such as a Nuclear Factor of Activated T cells (NF-AT) protein and/or an AP-1 family protein. Compositions for modulating Th2-associated cytokine production, recombinant expression vectors and host cells, as well as screening assays to identify agents that modulate c-Maf activity, are also disclosed.

6410261, Jun 25, 2002

Nov 6, 1997

08/965272

Laurie H. Glimcher - West Newton MA
Hong Zhou - Wilmington DE

President and Fellows of Harvard College - Cambridge MA

C07H 2102

435 691, 536 231, 536 235, 4353201, 435325, 435455, 4352523, 530350

Isolated nucleic acid molecules encoding a novel protein, CIP104, that interacts with CIITA, an MHC class II transcriptional activator, are disclosed. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a CIP104 transgene. The invention further provides isolated CIP104 proteins and peptides, CIP104 fusion proteins and anti-CIP104 antibodies. Methods of using the CIP104 compositions of the invention are also disclosed, including methods for detecting CIP104 activity (e. g. , CIP104 protein or mRNA) in a biological sample, methods of modulating CIP104 activity in a cell, and methods for identifying agents that modulate an interaction between CIP104 and CIITA.

6537810, Mar 25, 2003

Nov 25, 1996

08/755592

Laurie H. Glimcher - West Newton MA
I-Cheng Ho - Newton MA

President and Fellows of Harvard College - Cambridge MA

C12N 1567

435375, 435 691, 435455

Methods for modulating production of a T helper type 2 (Th2)-associated cytokine, in particular interleukin-4, by modulating the activity of one or more transcription factors that cooperate with NF-AT family proteins to regulate expression of a Th2-associated cytokine gene are disclosed. In one embodiment, the activity of a maf family protein (e. g. , c-Maf or a small maf protein, such as p18) is modulated. In another embodiment, the activity of a protein that interacts with an NF-AT family protein (e. g. , NIP45) is modulated. Combination methods, for example wherein the activities of a maf family protein and an NF-AT protein are modulated or the activities of a maf protein and and NF-AT-interacting protein are modulated, are also encompassed by the invention. Methods for modulating development of T helper type 1 (Th1) or T helper type 2 (Th2) subsets in a subject using agents that modulate transcription factor activity are also disclosed.

6548734, Apr 15, 2003

May 28, 1999

09/322624

Laurie H. Glimcher - West Newton MA
Ann M. Ranger - Brighton MA

President and Fellows of Harvard College - Cambridge MA

G01N 3300

800 3, 424 91, 424 92, 435 4, 435 6, 800 13, 800 14, 800 18

The invention demonstrates that NFATp represses cartilage cell division and represses the chondrogenic program in cells and displays the properties of a tumor suppressor gene. In addition, the invention demonstrates that inhibition of NFATp activity promotes cartilage cell proliferation and differentiation. Methods for identifying modulators of cartilage growth and/or differentiation, using either NFATp-deficient cells or NFATp-containing indicator compositions, are provided. Methods of modulating cartilage cell growth and/or differentiation using agents that modulate the activity of NFATp are also provided. Methods for diagnosing disorders associated with aberrant cartilage cell growth and/or differentiation, by assessing a change in NFATp expression, are also provided.

6573365, Jun 3, 2003

Jul 17, 2000

09/617923

Laurie H. Glimcher - West Newton MA
Martin R. Hodge - Arlington MA

President and Fellows of Harvard College - Cambridge MA

C07K 1624

53038822, 5303871, 5303879, 5303881, 5303882, 5303911, 5303913

Isolated nucleic acid molecules encoding a novel protein, NIP45, that interacts with members of the Nuclear Factor of Activated T cell (NF-AT) family of proteins, are disclosed. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a NIP45 transgene. The invention further provides isolated NIP45 proteins and peptides, NIP45 fusion proteins and anti-NIP45 antibodies. Methods of using the NIP45 compositions of the invention are also disclosed, including methods for detecting NIP45 protein or mRNA in a biological sample, methods of modulating NIP45 activity in a cell, and methods for identifying agents that modulate an interaction between NIP45 and an NF-AT family protein.

6632608, Oct 14, 2003

Dec 29, 2000

09/753346

Laurie H. Glimcher - West Newton MA
Andreas M. Reimold - Chestnut Hill MA

President and Fellows of Harvard College - Cambridge MA

C12Q 168

435 6, 435 4, 435 71, 435 691, 435372, 4353721, 4353722, 4353723, 536 235, 536 241

The invention demonstrates that the transcription factor XBP-1 is a regulator of hepatocyte growth, plasma cell differentiation and T cell subset activity. Methods for identifying modulators of hepatocyte growth, plasma cell differentiation and/or T cell subset activity, using XBP-1-containing indicator compositions or XBP-1-deficient cells, are provided. Methods of modulating hepatocyte growth, plasma cell differentiation and/or T cell subset activity (e. g. , Th2 cytokine production) using agents that modulate the activity of XBP-1 are also provided. Methods for diagnosing disorders associated with aberrant hepatocyte growth, plasma cell differentiation and/or T cell subset activity, by assessing a change in XBP-1 expression, are also provided. XBP-1 deficient cells, animals and embryos, as well as kits for the methods of the invention, are also provided by the invention.

6933125, Aug 23, 2005

Jun 12, 2001

09/879312

Laurie H. Glimcher - West Newton MA, US
John Douhan, III - Boston MA, US

President and Fellows of Harvard College - Cambridge MA

C12P021/06

435 91, 435325, 424 931, 536 231

Isolated nucleic acid molecules encoding human c-Maf, and isolated c-Maf proteins, are provided. The invention further provides antisense nucleic acid molecules. recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a human c-Maf transgene. The invention further provides human c-Maf fusion proteins and anti-human c-Maf antibodies. Methods of using the human c-maf compositions of the invention are also disclosed, including methods for detecting human c-Maf activity in a biological sample, methods of modulating human c-Maf activity in a cell, and methods for identifying agents that modulate the activity of human c-Maf.

6967077, Nov 22, 2005

Feb 12, 1999

09/248756

Laurie H. Glimcher - West Newton MA, US
I-Cheng Ho - Newton MA, US

President and Fellows of Harvard College - Cambridge MA

C12N015/00
C12N015/09
C12N015/86
C12Q001/68
C07H021/04

435 6, 435 4, 435 29, 435375, 4353201, 435325, 435455, 536 231

Methods for modulating production of a T helper type 2 (Th2)-associated cytokine, in particular interleukin-4, by modulating the activity of a transcription factor, in particular the proto-oncoprotein c-Maf, that regulates expression of the Th2-associated cytokine gene are disclosed. Methods for modulating development of T helper type 1 (Th1) or T helper type 2 (Th2) subsets in a subject using agents that modulate transcription factor activity are also disclosed. The methods of the invention can further involve use of agents that modulate the activity of additional transcription factors that contribute to the regulation of Th1- or Th2-associated cytokines, such as a Nuclear Factor of Activated T cells (NF-AT) protein and/or an AP-1 family protein. Compositions for modulating Th2-associated cytokine production, recombinant expression vectors and host cells, as well as screening assays to identify agents that modulate c-Maf activity, are also disclosed.